Key result
Only 47% of patients with acute atherosclerotic cardiovascular disease were managed according to the 2018 ACC/AHA blood cholesterol recommendations, while 53% did not receive appropriate statin therapy.
Why the study?
Real-world observations of changes in cholesterol treatment and doctors adherence to the 2018 ACC/AHA recommendations had not been studied in Saudi Arabia.
Cohort (n=139)
No
Answers are grounded in this paper and cite their sources.
More than half of patients with acute atherosclerotic cardiovascular disease in a Saudi Arabian hospital did not receive guideline-recommended statin therapy, highlighting a significant gap in guideline implementation.
Background: The updated 2018 American College of Cardiology (ACC) and American Heart Association (AHA) blood cholesterol treatment guideline showed a major shift in treating atherosclerotic cardiovascular disease (ASCVD). In 2018 they recommendations were adopted to increase the number of persons using statin therapy, but the real-world observations especially in Saudi Arabia of how treatment use has changed has been limited in the literature. Doctors' involvement to ACC/AHA 2018 recommendations regarding prescribing medications have not been studied in Saudi Arabia.· Aim: To examine doctors' involvement to ACC/AHA 2018 cholesterol recommendations in managing patients with any acute atherosclerotic cardiovascular disease. How they follow the role of prescribing statin medications and the proper doses for statin or other anti-cholesterol medications.· Results : Around 47% of the patients were managed according to the 2018 ACC/AHA recommendations. On the other hand, 53% of patients did not take statin. Doctors found to be adhering to the recommendations when managing patients with myocardial infarction and unstable angina in contrast to other astherovascular events. For the non-adherent patients 40% of them refused because of their own believes or the fear of the side effects.· Conclusion: our primary analysis concluded that around more than half of the patients with acute atherosclerotic diseases were not given the recommended statin by the 2018 ACC/AHA blood cholesterol recommendations, moreover some of them did not receiving any statin therapy.
No takes yet. Share an insight, caveat, or question.
Alhindi et al. (2022) conducted a cohort in Acute atherosclerotic cardiovascular disease (ASCVD) (n=139). Adherence to 2018 ACC/AHA blood cholesterol treatment recommendations vs. Non-adherence was evaluated on Proportion of patients managed according to the 2018 ACC/AHA blood cholesterol recommendations. Only 47% of patients with acute atherosclerotic cardiovascular disease were managed according to the 2018 ACC/AHA blood cholesterol recommendations, while 53% did not receive appropriate statin therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: